Convatec, a UK medical products and technologies developer, today announces plans to invest more than $1 billion over the next decade to accelerate its research and development (R&D) ambitions worldwide.
As part of this plan, Convatec will invest $600 million over the next ten years in R&D in the USA, underlining the company’s long-term commitment to its most significant market globally. The plans include a significant expansion of its world-class R&D facilities in Boston, USA, by end 2025 – increasing capacity by 50% and further enhancing lab, testing and collaboration space.
In the UK, Convatec plans to invest £500 million (~$650 million), including a new state-of-the-art R&D hub in Manchester, set to open in 2027. The new facility will be one of the largest in Convatec’s global network of Technology & Innovation Centers, with the potential to provide common or shared R&D capabilities and competences across all four of Convatec’s categories: advanced wound care, ostomy care, continence care, and infusion care. It will also house cutting-edge analytical R&D capabilities, regulatory functions, and digital health innovation, positioning Convatec at the forefront of medical technology development.
